investigators and is one of the most consistent findings across tumor types. The increased metabolism of tumors for glucose and its analogs, such as FDG, is the basis for the burgeoning role of PET imaging in oncology (5) . The magnitude of the Warburg effect in tumors can be very large, with an increase in uptake that may be 10 -100-fold greater than the tissue from which the tumor cells arise. It appears that expression levels and enhanced binding to mitochondria of glucose to key enzymes such as hexokinase II are also important in the rate of glucose metabolism by human tumors (6) . Thus, hypoxia alone does not appear to be the sole cause for the increase in glucose metabolism that is observed in cancer cells.
It can be shown that the standardized uptake value (SUV max ) is proportional to the rate of glucose metabolism (7) . Now that PET-FDG is being widely used in clinical oncology, it has become evident that the rate of glycolysis, as captured by the SUV max or related uptake measures, is an important predictor of the biological aggressiveness across multiple tumor types, including brain tumor (8) , sarcoma (9), thyroid cancer (10), head and neck cancer (11) , non-small cell lung cancer (12, 13) , malignant mesothelioma (14) , prostate cancer (15), small cell lung cancer (16) , esophageal carcinoma, pancreatic tumors (17, 18) , and non-Hodgkin's lymphoma (19) . These articles are but examples; there are numerous additional articles showing that the higher the glucose metabolism seen on FDG-PET imaging, the worse the prognosis, especially for untreated tumors [two tumors that may be exceptions (i.e., aggressive tumors with low uptake) are gastric cancer and hepatocellular carcinoma]. Nonetheless, it is clear that a great deal of biological information is contained within the PET-FDG SUV max measure of glycolysis, which correlates strongly with an adverse patient prognosis.
Hypoxia too, is associated with poor prognosis in several common human tumors (20) . Physicochemical effects of hypoxia in reducing response to radiation may explain some of these adverse effects. A variety of additional factors transcribed in response to hypoxia-inducible factor 1␣ binding with the hypoxia-responsive elements of DNA appear to actually cause the majority of the altered prognostic features of the hypoxic state (21) .
In summary, multiple reports provide clear evidence that hypoxia and accelerated glycolysis are common but independent manifestations of the phenotype of human malignancy. Although acute hypoxia can clearly provide a modest stimulus to glycolysis in normal tissues and some tumors, the link to hypoxia does not, in and of itself, appear strong enough for hypoxia to serve as a prime cause for the broad spectrum of accelerated glycolysis that appears to be a property of individual tumors both within and between diverse cancer types. Instead, emerging biological evidence suggests that the expression of hypoxia-inducible factor 1␣, which is itself induced by hypoxia along with a variety of other proproliferative and antiapoptotic stimuli action, is the best candidate thus far as the prime mover, behind both the characteristic hypoxia and increased glycolysis that are shared by many common human tumors. As such, hypoxia-inducible factor 1␣ would seem to be an excellent therapeutic target in cancer (22, 23) , and PET-based molecular imaging of hypoxia and glycolysis is likely to be useful as a marker for the effectiveness of anti-hypoxia-inducible factor 1␣ therapy.
